Liyan Y. Smeding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liyan Y. Smeding has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Ashraful Islam
Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, USA
1 shared publicationGualberto Gonzalez-Sapienza
Cátedra de Inmunología, Departamento de Biociencias (DEPBIO), Facultad de Química, Universidad de la República, Montevideo, Uruguay
1 shared publicationHarun R. Sugito
Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, USA
1 shared publication- Hidde Lolke Ploegh
Program in Cellular and Molecular Medicine, Boston Children’s Hospital
1 shared publication - Leif S. Ludwig
Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany
1 shared publication Martin A. Rossotti
Cátedra de Inmunología, Departamento de Biociencias (DEPBIO), Facultad de Química, Universidad de la República, Montevideo, Uruguay
1 shared publication
Latest Publications
- 14 June 2021
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 5 (11) , 1389-1401
Induction of antigen-specific tolerance by nanobody–antigen adducts that target class-II major histocompatibility complexes
The association of autoimmune diseases with particular allellic products of the class-II major histocompatibility complex (MHCII) region implicates the presentation of the offending self-antigens to T cells. Because antigen-presenting cells are tolerogenic when they encounter an antigen under non-inflammatory conditions, the manipulation of antigen presentation may induce antigen-specific tolerance. Here, we show that, in mouse models of experimental autoimmune encephalomyelitis, type 1 diabetes and rheumatoid arthritis, the systemic administration of a single dose of nanobodies that recognize MHCII molecules and conjugated to the relevant self-antigen under non-inflammatory conditions confers long-lasting protection against these diseases. Moreover, co-administration of a nanobody–antigen adduct and the glucocorticoid dexamethasone, conjugated to the nanobody via a cleavable linker, halted the progression of established experimental autoimmune encephalomyelitis in symptomatic mice and alleviated their symptoms. This approach may represent a means of treating autoimmune conditions.
- 14 June 2021
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 5 (11) , 1389-1401
Induction of antigen-specific tolerance by nanobody–antigen adducts that target class-II major histocompatibility complexes
The association of autoimmune diseases with particular allellic products of the class-II major histocompatibility complex (MHCII) region implicates the presentation of the offending self-antigens to T cells. Because antigen-presenting cells are tolerogenic when they encounter an antigen under non-inflammatory conditions, the manipulation of antigen presentation may induce antigen-specific tolerance. Here, we show that, in mouse models of experimental autoimmune encephalomyelitis, type 1 diabetes and rheumatoid arthritis, the systemic administration of a single dose of nanobodies that recognize MHCII molecules and conjugated to the relevant self-antigen under non-inflammatory conditions confers long-lasting protection against these diseases. Moreover, co-administration of a nanobody–antigen adduct and the glucocorticoid dexamethasone, conjugated to the nanobody via a cleavable linker, halted the progression of established experimental autoimmune encephalomyelitis in symptomatic mice and alleviated their symptoms. This approach may represent a means of treating autoimmune conditions.